Provided by Tiger Trade Technology Pte. Ltd.

Corbus Pharmaceuticals

10.38
+0.54005.49%
Post-market: 10.15-0.2300-2.22%19:30 EDT
Volume:604.02K
Turnover:6.15M
Market Cap:200.76M
PE:-1.70
High:10.42
Open:9.97
Low:9.90
Close:9.84
52wk High:20.56
52wk Low:7.12
Shares:19.34M
Float Shares:17.42M
Volume Ratio:1.33
T/O Rate:3.47%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-6.0889
EPS(LYR):-5.9000
ROE:-95.58%
ROA:-53.00%
PB:1.96
PE(LYR):-1.76

Loading ...

Company Profile

Company Name:
Corbus Pharmaceuticals
Exchange:
NASDAQ
Establishment Date:
2009
Employees:
36
Office Location:
500 River Ridge Drive,Norwood,Massachusetts,United States
Zip Code:
02062
Fax:
- -
Introduction:
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.

Directors

Name
Position
Yuval Cohen
Chief Executive Officer and Director
Rachelle Jacques
Chair of the Board and Director
Anne Altmeyer
Director
John Jenkins
Director
Winston Kung
Director
Yong Ben
Director

Shareholders

Name
Position
Yuval Cohen
Chief Executive Officer and Director
Ian Hodgson
Chief Operating Officer
Sean Moran
Chief Financial Officer
Dominic Smethurst
Chief Medical Officer